Hospira, Inc. recalled 49,620 vials of Epinephrine Injection on August 4, 2025. The recall follows concerns about the lack of assurance of sterility. Consumers should stop using the product immediately.
Lack of Assurance of Sterility.
Consumers and healthcare providers should stop using this product immediately. Contact PFIZER INC or your healthcare provider for guidance. Notification method: Letter
The recalled product is Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL). It was distributed by Hospira, Inc. and is identified by NDC 0409-4933-05.
The recall stems from a lack of assurance of sterility. This poses a high risk of infection and serious health complications for users.
No specific incidents or injuries have been reported at this time. The risk remains high due to the potential for contamination.
Stop using the product immediately. Contact Pfizer Inc. or your healthcare provider for guidance on returning the product.
For more information, visit the FDA recall page or contact Pfizer Inc. directly for assistance and guidance.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.